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Abstract
Case report We describe the case of a 73-year-old woman who was diagnosed with herpes simplex virus-1 encephalitis during
the COVID-19 pandemic. The diagnosis was somehow delayed because relatives were initially cautious in bringing the patient to
the hospital and, here, the work-up focus was on coronavirusrelated aspects as the patient was initially reputed to be infected with
COVID-19.
Conclusions During the current viral outbreak, physicians should not neglect the possibility of other diseases that represent
neurological emergencies and require immediate recognition and treatment.
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Introduction
The current COVID-19 pandemic is nowadays heavily affecting
each person’s life and also the everyday work of many doctors.
The outbreak has had a dramatic impact on neurology practice
with effects at various levels, from the treatment of acute neuro-
logical patients, such as those with stroke, to the care of patients
with chronic neurological diseases [1], but also in terms of train-
ing of medical students and residents, and even considering the
way the usual neurological patients are approached.
Only a few days before the COVID-19 outbreak, a certain
clinical presentation would have been interpreted in a quite
standardized way on the basis of history, symptoms, and signs,
and it would have led to ask for a series of radiological and
laboratory investigations. Based on clinical elements and re-
sults of investigations, a diagnosis would have been generated
and appropriate therapy introduced. Today, in the COVID-19
era, a patient can be at risk of receiving a misdiagnosis, espe-
cially in the emergency setting, because symptoms like fever,
tachypnea, and consciousness alteration may be interpreted as
solely related to a COVID-19 infection with the consequent
primary target of excluding it, for example for decreasing the
risk of contagion. This approach, induced by the fear and
high-level stress induced by the pandemic on the health care
personnel, can generate some delay in the correct diagnosis
and therapy initiation, or even a misdiagnosis with all the
possible consequences.
Case report
A 73-year-old woman arrived at the emergency room (ER) be-
cause in the morning she was found unresponsive and febrile in
the bed. The patient has had a fever for the 3 previous days and,
in the afternoon before hospitalization, she had been seen clum-
sy in movement and slowed in reasoning and speech. Her sister
had attributed this condition to the febrile state and a possible,
yet non-testified, epileptic event, because the patient had a his-
tory of epilepsy since the age of 62; consequently, she decided
not to carry the patient to ER or to call her family practitioner.
The patient had been on valproic acid (VPA) 300 mg b.i.d. for
the last 5 years with incomplete control of crises (a couple of
episodes of generalized seizure/year). Laboratory exams, includ-
ing liver function markers and VPA levels, had always been
within the range of normality since then.
On ER admission, the first diagnostic hypothesis was a
possible COVID-19 infection, also supported by a reduced
oxygen saturation (90%) that required oxygen treatment. A
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nasopharyngeal swab was taken. A brain CT scan showed
diffuse hypodensity of the left cerebral hemisphere (Fig. 1a)
that was reported as a possible ischemic lesion. As a conse-
quence, the patient underwent an angio-CT scan of the neck
vessels and intracranial arteries which did not show any sig-
nificant alteration.
Only at this time, a neurological evaluation was requested
to evaluate what was advanced to be a “cerebral ischemic
stroke in a possibly COVID-19 positive patient.” On the ER
neurological examination, the Glasgow Coma Scale was 7
(E2, V1, M4): the patient had a response with facial grimaces
to painful neck stimulus on both sides of the body. A normal
flexion of lower limbs was obtained after a painful fingertip
stimulus, prevalent on the left. The patient maintained her eyes
opened after a painful stimulus for 20–25 s without exploring
the surrounding environment. No audible verbal response was
present. No difference was shown in pupil diameter and re-
sponse to light. Corneal reflex was symmetrically present.
The progressive worsening of vigilance in the last 36 h
before hospitalization, the absence of a manifest sudden
onset, the presence of fever for a few days, the history of
epilepsy, and the antiepileptic therapy currently below the
therapeutic range (VPA plasmatic levels 20.8 mg/L; ther-
apeutic range 50–100 mg/L) did not sustain the diagnosis
of an acute cerebral ischemic event, while they seemed to
support the hypothesis of epileptic status or, secondly, of
an encephalitic process.
The electroencephalogram (EEG) showed diffuse slow
activity and continuous epileptic activity on the left
centrotemporal regions (Fig. 2a). A rapid, i.e., infusion of
8 mg of lorazepam induced a rapid change of EEG with the
disappearance of the continuous epileptic activity, and the
appearance of bilateral synchronous periodic discharges,
with the highest amplitude on the left hemisphere, at about
0.2–0.3 cps, suggestive for possible limbic encephalitis,
most likely herpetic (Fig. 2b). A lumbar puncture was then
performed in the ER. The cerebrospinal fluid (CSF) was
slightly hematic. The CSF analysis showed a high protein
concentration (3380 mg/L) and an increased amount of
white blood cel ls (108 cel ls /mL, of which 42%
Fig 1 a Computed tomography
scan in the emergency room
showing diffuse hypodensity of
the left temporal lobe. b–d Brain
magnetic resonance imaging 5
days after hospitalization. b
Coronal FLAIR (fluid-attenuated
inversion recovery). c and dAxial
T2 weighted. The MRI shows
fronto-basal, temporo-occipital,
and insular lesions in the left
hemisphere and temporo-insular
lesions of the right hemisphere
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mononuclear cells and 58% polymorphonuclear cells.
Herpes simplex virus-1 (HSV-1) DNA was found in CSF
in large amount (142,387 copies/mL; normal < 250). The
COVID-19 RT-PCR test was negative in both the CSF and
the nasopharyngeal swab.
The diagnosis was that of an epileptic status caused by
HSV-1 encephalitis. Therapy with intravenous acyclovir was
started, and the VPA daily dose was incremented to 1300 mg/
day. The patient became afebrile and partial neurological re-
covery was obtained after 3 days.
A few days after hospitalization, the patient underwent an
MRI study which showed the extension of the cerebral dam-
age and confirmed a distribution typical for herpetic enceph-
alitis (Fig. 1 b, c, and d ).
Discussion
This case report highlights a few issues that need to be con-
sidered in this time of COVID-19 outbreak, particularly the
fact that other emergencies are not disappeared and should be
considered in the differential diagnosis, today as in the past.
The diagnosis of HSV-1 encephalitis was somehow delayed in
this patient for a number of reasons. The first one was a pos-
sible delay in the delivery of this patient to the ER, possibly
because relatives were scared of bringing the patient to an
environment reputed at high risk of COVID-19 contagion.
In fact, while the general Italian population has been invited
to stay home in the case of fever and to call the general prac-
titioner to reduce the patient burden of ER, many people do
Fig. 2 EEG recordings in the
emergency room. a Continuous
epileptic activity on the left
centrotemporal regions. b After
IV lorazepam 8 mg, bilateral
synchronous periodic discharges,
with highest amplitude on the left
hemisphere, at about 0.2–0.3 cps
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not know about the presence of differentiated COVID+ and
COVID-free pathways in the ER. Second and perhaps more
relevant, the fact that in the ER, each patient is today first
hypothesized to have a COVID-19-related condition, a con-
viction that forces many colleagues to first working to exclude
it, before of hypothesizing other diseases, on the basis of
symptoms and history. Even the presence of a possible ische-
mic lesions, and therefore the diagnosis of stroke, was related
in the ER to an underlying COVID-19 infection, perhaps in
relation to the emerging news about the supposed presence of
a thrombophilia induced by the COVID-19 [2, 3].
All the above issues might have led to a delay in starting the
therapy and therefore to an increased risk of incomplete re-
covery from the HSV-1 infection. Thus, the COVID-19 pan-
demic poses everybody at a higher risk of making a certain
amount of indirect victims related to COVID-induced misdi-
agnosis. In this regard, it should be noted that despite the
involvement of the central nervous system in COVID-19 in-
fection has been frequently mentioned, only 2 cases of en-
cephalitis caused by this infection have been reported [4, 5].
In one of these reports, however, the virus was not detected in
the CSF and an immune-mediated mechanism of injury was
postulated [4]. Therefore, in case of signs and symptoms of
encephalitis in COVID-19 patients, also other causes of dam-
age to the nervous systems should be carefully considered.
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